Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Journal: Nature Communications

Published: 2020-07-30

DOI: 10.1038/s41467-020-17644-0

Affiliations: 20

Authors: 30

Go to article
Institutions Share
Institute Gustave-Roussy (IGR), France 0.25
Cordelier Research Center (CRC), France 0.24
Department of Radiation Oncology, Cornell University, United States of America (USA) 0.12
Institute of Medical Immunology, MLU, Germany 0.07
Caryl and Israel Englander Institute for Precision Medicine (IPM), Cornell University, United States of America (USA) 0.06
Sotio, a.s., Czech Republic 0.06
Faculty of Medicine, UPSud, France 0.04
Sandra and Edward Meyer Cancer Center, Cornell University, United States of America (USA) 0.04
Centre d'Immunologie et des Maladies Infectieuses (CIMI), France 0.03
2nd Faculty of Medicine, CU, Czech Republic 0.02
University Hospital in Motol, Czech Republic 0.02
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.01
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.01
Georges Pompidou European Hospital (HEGP), France 0.01
Suzhou Institute of Systems Medicine (ISM), CAMS & PUMC, China 0.01
Karolinska University Hospital, Sweden 0.01
Yale Department of Dermatology, United States of America (USA) 0.01
University of Paris, France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER